Nifty Healthcare Index News and Updates

Name: Latest research reports of Biocon Ltd. authored by Axis Direct and published by - Trendlyne research reports.
Item: Biocon Ltd.
Rating: 5
Author: Axis Direct

Keep track of all breaking news on Nifty Healthcare Index from all sources in a single place.

Lupin Ltd.

01 Dec 2025, 03:45PM

2081.90

-0.01%

Lupin Gets USFDA Nod For Biosimilar Drug

NDTV Profit

Armlupeg is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs.

Lupin Ltd. is trading above all available SMAs

Lupin gets USFDA nod for biosimilar drug

Business Line | 01 Dec 2025, 12:26PM 1 more

Sun Pharmaceutical Industries Ltd.

01 Dec 2025, 12:01PM

1807.40

-1.32%

Sun Pharma launches plaque psoriasis drug ILUMYA in India

Business Line

A novel biologic treatment, ILUMYA (Tildrakizumab) has been endorsed widely by dermatologists in the US and worldwide for several years as an effective and safe treatment of moderate to severe plaque psoriasis

Promoters pledged 0.09% of shares in last quarter. Total pledge stands at 0.97% of promoter holdings

Sun Pharma launches Ilumya in India to expand advanced psoriasis treatment

Business Standard | 01 Dec 2025, 11:30AM

Biocon Ltd.

29 Nov 2025

394.50

-0.97%

Pick of the Week:Biocon

Buy: Biocon Ltd.

Target

Axis Direct

BUY with a target price of Rs 440, implying an upside of ~10% from the CMP.

Biocon Ltd. is trading above all available SMAs

Cipla Ltd.

28 Nov 2025

1523.10

-0.54%

Cipla opens lung centre in Delhi

Business Line

Cipla launches a Breathefree Lung Wellness Center in Delhi to enhance lung diagnostics amid rising respiratory diseases and air pollution.

Cipla Ltd. has an average target of 1703.00 from 9 brokers.

Cipla launches India's first integrated lung diagnostics, wellness centre

Business Standard | 28 Nov 2025

Torrent Pharmaceuticals Ltd.

28 Nov 2025

3736.90

0.44%

GST authority imposes Rs 41 cr penalty on Torrent Pharmaceuticals

Business Standard

Torrent Pharmaceuticals Ltd on Friday said the central GST authority has imposed a penalty of over Rs 41 crore on the company for alleged erroneous refund on export of goods. The Joint Commissioner, Common Adjudicating Authority, Central GST, Ahmedabad South Commissionerate passed an order imposing a penalty of Rs 41,33,84,165, Torrent Pharmaceuticals Ltd said in a regulatory filing. The order dated November 26, 2025 alleges erroneous refund by department on export of goods, it added. The company further said based on its assessment, an appeal will be filed and is hopeful of favourable outcome and does not reasonably expect the order to have any material financial impact on it.

Torrent Pharmaceutic.. has an average target of 3880.00 from 6 brokers.

Glenmark Pharmaceuticals Ltd.

27 Nov 2025

1941.70

-0.23%

Glenmark's Monroe facility classified as voluntary action indicated by USFDA

Business Line

The inspection was conducted at the company's manufacturing facility from June 9 to June 17, 2025, Glenmark Pharmaceuticals Ltd said in a statement

Glenmark Pharmaceuti.. has an average target of 2086.50 from 5 brokers.

Glenmark Pharma gains 2% on positive US FDA inspection report; details here

Business Standard | 27 Nov 2025

Sun Pharmaceutical Industries Ltd.

26 Nov 2025

1807.40

-1.32%

Sun Pharma sees Golden Cross; other pharma stocks with similar pattern

Business Standard

Technically, the term 'Golden Cross' has bullish implications with short-term support seen moving higher. Apart from Sun Pharma, Aurobindo Pharma and Divi's Labs too witnessed this formation recently.

Promoters pledged 0.09% of shares in last quarter. Total pledge stands at 0.97% of promoter holdings

Mankind Pharma Ltd.

26 Nov 2025

2229.80

-0.94%

MANKIND PHARMA LIMITED

Buy: Mankind Pharma Ltd.

Recommendation Target

Geojit BNP Paribas

*over or under performance to benchmark index Mankind Pharma is an Indian multinational pharmaceutical and healthcare product company, headquartered in New Delhi. The company has products in therapeutic areas...

Mankind Pharma Ltd. is trading below all available SMAs

Max Healthcare Institute Ltd.

25 Nov 2025

1125.40

-3.22%

Max Healthcare Delivers Strong Growth Across Verticals in FY Performance Update

NDTV Profit

Max Healthcare continues its impressive growth trajectory under the leadership of CMD Abhai Soi. The company reported robust revenue gains driven by higher OPD visits and a favorable tax impact boosting PAT. EBITDA per bed in existing units rose 7% year-on-year, while Max Lab, the non-captive pathology division, grew 16%. International patient revenue surged 25%, underscoring global trust in Max's excellence.

Number of FII/FPI investors decreased from 1145 to 1089 in Sep 2025 qtr

Glenmark Pharmaceuticals Ltd.

25 Nov 2025

1941.70

-0.23%

Glenmark Pharma stock gains 3% on launch novel COPD treatment; details here

Business Standard

The company has launched Nebzmart GFB Smartules and Glenmark Airz FB Smartules, world's first nebulised, fixed-dose triple therapy for the treatment of Chronic Obstructive Pulmonary Disease (COPD)

Glenmark Pharmaceuti.. has an average target of 2086.50 from 5 brokers.

Nifty Healthcare Index PB	5.6
Nifty Healthcare Index PE	37.4
Nifty Healthcare Index DIV	0.6
Nifty Healthcare Index EPS	398.5

Near 52W High of ₹15112.50

Nifty Healthcare Index PB

Nifty Healthcare Index PE

Nifty Healthcare Index DIV

Nifty Healthcare Index EPS

Nifty Healthcare Index News and Updates

Keep track of all breaking news on Nifty Healthcare Index from all sources in a single place.